You can buy or sell Grifols and other stocks, options, ETFs, and crypto commission-free!
Grifols, S.A. American Depositary Shares, also called Grifols, is a vertically integrated global producer of plasma derivatives. Read More Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials Segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
52 Week High
52 Week Low
Simply Wall StMar 18
If You Had Bought Grifols (BME:GRF) Stock Three Years Ago, You Could Pocket A 26% Gain Today
One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. For example, the Grifols, S.A. (BME:GRF) share price is up 26% in the last three years, clearly besting than the market return of around 5.9% (not including dividends). However, more recent returns haven’t been as impressive as that, with the stock returning just 4.2% in the last year, including dividends. View our latest analysis for Grifols While marke...
Seeking AlphaMar 10
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Deals and Financings Grifols (MCE: GRF, GRFS), a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS (SHZ: 002252), one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidiary, Grifols Diagnostic Solutions, for the Shanghai RAAS stake. As part of the agreement, Shanghai RAAS will become exclusive distributor of Grifols' plasma-based and diagnostic products in China, including Grifol's nucleic aci...
$0.24 per share
Expected Mar 27, Pre-Market